MAPT and Alzheimer disease: Assessments of these lesions form the basis for the neuropathological confirmation of a clinical diagnosis of probable AD according to the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) protocol [2, 3] and the assessment of tau-immunoreactive (IR) changes according to Braak stage [4, 5].